Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Serum Levels of Meteorin-Like (Metrnl) Are Increased in Patients with Newly Diagnosed Type 2 Diabetes Mellitus and Are Associated with Insulin Resistance

Serum Levels of Meteorin-Like (Metrnl) Are Increased in Patients with Newly Diagnosed Type 2... BackgroundMeteorin-like (Metrnl) is a novel adipomyokine that may improve glucose tolerance and affect insulin resistance. This study aimed to investigate the association between serum levels of Metrnl with blood glucose status and to its association with insulin resistance.Material/MethodsThe study included 160 subjects with normal glucose tolerance (NGT) (n=40), impaired fasting glucose (IFG) (n=40), impaired glucose tolerance (IGT) (n=40), and newly diagnosed type 2 diabetes mellitus (T2DM) (n=40). An enzyme-linked immunosorbent assay (ELISA) was used to measure the serum levels of Metrnl. Partial correlation analysis was used to analyze the relationship between serum levels of Metrnl and metabolic parameters. Multiple logistic regression analysis was performed to identify the association between serum levels of Metrnl with the risk of diabetes.ResultsSerum levels of Metrnl was highest in patients with T2DM and significantly increased in patients with prediabetes compared with individuals with NGT. After adjusting for age, gender, and body mass index (BMI), serum Metrnl level was significantly correlated with lipid profile, glucose profile, and insulin resistance. Multiple logistic regression analysis showed that Metrnl significantly increased the risk of T2DM (OR=1.727; P=0.008) before adjusting for the homeostatic model assessment of insulin resistance (HOMA-IR). When further adjusted for HOMA-IR, Metrnl was no longer associated with an increased OR for T2DM (OR=1.491; P=0.066), while the HOMA-IR significantly increased the risk of T2DM (OR=1.935; P=0.008).ConclusionsSerum levels of Metrnl were significantly increased in patients with T2DM and may increase the risk of T2DM independent of insulin resistance. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Medical Science Monitor : International Medical Journal of Experimental and Clinical Research Pubmed Central

Serum Levels of Meteorin-Like (Metrnl) Are Increased in Patients with Newly Diagnosed Type 2 Diabetes Mellitus and Are Associated with Insulin Resistance

Medical Science Monitor : International Medical Journal of Experimental and Clinical Research , Volume 25 – Mar 31, 2019
7 pages

Loading next page...
 
/lp/pubmed-central/serum-levels-of-meteorin-like-metrnl-are-increased-in-patients-with-RpKFYjF0Mf

References (27)

Publisher
Pubmed Central
Copyright
© Med Sci Monit, 2019
ISSN
1234-1010
eISSN
1643-3750
DOI
10.12659/MSM.915331
Publisher site
See Article on Publisher Site

Abstract

BackgroundMeteorin-like (Metrnl) is a novel adipomyokine that may improve glucose tolerance and affect insulin resistance. This study aimed to investigate the association between serum levels of Metrnl with blood glucose status and to its association with insulin resistance.Material/MethodsThe study included 160 subjects with normal glucose tolerance (NGT) (n=40), impaired fasting glucose (IFG) (n=40), impaired glucose tolerance (IGT) (n=40), and newly diagnosed type 2 diabetes mellitus (T2DM) (n=40). An enzyme-linked immunosorbent assay (ELISA) was used to measure the serum levels of Metrnl. Partial correlation analysis was used to analyze the relationship between serum levels of Metrnl and metabolic parameters. Multiple logistic regression analysis was performed to identify the association between serum levels of Metrnl with the risk of diabetes.ResultsSerum levels of Metrnl was highest in patients with T2DM and significantly increased in patients with prediabetes compared with individuals with NGT. After adjusting for age, gender, and body mass index (BMI), serum Metrnl level was significantly correlated with lipid profile, glucose profile, and insulin resistance. Multiple logistic regression analysis showed that Metrnl significantly increased the risk of T2DM (OR=1.727; P=0.008) before adjusting for the homeostatic model assessment of insulin resistance (HOMA-IR). When further adjusted for HOMA-IR, Metrnl was no longer associated with an increased OR for T2DM (OR=1.491; P=0.066), while the HOMA-IR significantly increased the risk of T2DM (OR=1.935; P=0.008).ConclusionsSerum levels of Metrnl were significantly increased in patients with T2DM and may increase the risk of T2DM independent of insulin resistance.

Journal

Medical Science Monitor : International Medical Journal of Experimental and Clinical ResearchPubmed Central

Published: Mar 31, 2019

There are no references for this article.